多动脉血运重建中桡动脉与大隐静脉桥的长期结局与通畅性
该前瞻性纵向研究纳入1654例多动脉血运重建患者,中位随访7.4年,比较双侧内乳动脉(BITA)联合或不联合桡动脉(RA)以及RA与大隐静脉桥的临床结局。结果显示BITA组生存率、无主要不良心脑血管事件生存率更优且再次血运重建需求更低,RA桥闭塞和靶血管血运重建风险低于大隐静脉桥。
要点
- BITA组生存、无主要不良心脑血管事件生存优于非BITA组,再次血运重建需求更低。
- RA桥闭塞风险低于大隐静脉桥(OR 0.59,95%CI 0.47-0.73,P<.001)。
- RA桥靶血管血运重建风险低于大隐静脉桥(SHR 0.58,95%CI 0.43-0.78,P<.001)。
核心结论
- 多动脉血运重建中采用BITA联合RA移植是冠状动脉旁路移植术实现长期获益的推荐策略。
- 大隐静脉桥在通畅性和靶血管血运重建需求方面结局较差。
研究设计与样本
- 前瞻性纵向研究,2001年至2016年纳入1654例患者,中位随访7.4年。
- 采用倾向评分校正Cox回归、广义估计方程和竞争风险模型分析。
- 910例(55.0%)接受BITA移植,744例(45.0%)接受左内乳动脉联合至少1根RA移植。
- BITA组中187例额外接受RA移植。
- 亚组512例患者中比较419根RA与487根大隐静脉桥。
主要发现
- BITA组生存改善(HR 0.57,95%CI 0.38-0.86,P=.009)。
- BITA组无主要不良心脑血管事件生存改善(HR 0.33,95%CI 0.23-0.46,P<.001)。
- BITA组再次血运重建需求更低(SHR 0.59,95%CI 0.39-0.90,P=.015)。
- RA桥闭塞风险低于大隐静脉桥(OR 0.59,95%CI 0.47-0.73,P<.001)。
- RA桥靶血管血运重建风险低于大隐静脉桥(SHR 0.58,95%CI 0.43-0.78,P<.001)。
临床怎么用
- 在冠状动脉旁路移植术多动脉血运重建中,可优先考虑BITA联合RA移植以改善长期结局。
- 选择桥血管时需权衡大隐静脉桥较高的闭塞和靶血管血运重建风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The long-term benefits of multiple arterial revascularization (MAR) in coronary artery bypass grafting remain uncertain. The aim of this study was to investigate the clinical outcome, graft patency, and need for subsequent target revascularization of radial artery (RA) versus saphenous vein graft in patients undergoing MAR in both patient- and graft-specific analyses. METHODS: Between 2001 and 2016, we followed 1654 patients over a median of 7.4 years in a prospective, longitudinal study. Major adverse cardiac and cerebrovascular events, graft patency, and need for revascularization were assessed through clinical manifestation, coronary angiography, or coronary computed tomography and analyzed with propensity score-adjusted Cox regression, general estimating equation, and competing risk models. RESULTS: Bilateral internal thoracic artery (BITA) grafting was performed in 910 patients (55.0%), and 744 patients (45.0%) received a left internal thoracic artery graft together with at least 1 RA graft. Patients receiving BITA, of whom 187 received an additional RA, showed improved survival (hazard ratio, 0.57; 95% confidence interval [CI], 0.38-0.86; P = .009), major adverse cardiac and cerebrovascular event-free survival (hazard ratio, 0.33; 95% CI, 0.23-0.46; P < .001), and lower need for repeat revascularization (subhzhard ratio, 0.59; 95% CI, 0.39-0.90; P = .015). In a subgroup of 512 patients, comparing 419 RA with 487 saphenous vein grafts, RA grafting showed a lower risk for graft occlusion (odds ratio, 0.59; 95% CI, 0.47-0.73; P < .001) and target revascularization (subhazard ratio, 0.58; 95% CI, 0.43-0.78; P < .001). CONCLUSIONS: MAR with BITA and RA grafting revealed to be the recommended strategy in coronary artery bypass grafting to achieve long-term beneficial results. The use of saphenous vein graft showed less favorable outcomes regarding patency and the need for target-vessel revascularization.
引用
- Ruttmann E, Dietl M, Feuchtner GM, et al. Long-term clinical outcome and graft patency of radial artery and saphenous vein grafts in multiple arterial revascularization. J Thorac Cardiovasc Surg. 2018. PMID: 30551960. doi:10.1016/j.jtcvs.2018.10.135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。